卵巢癌组织多药耐药性的临床研究

CLINICAL STUDY OF MULTIDRUG RESISTANCE IN OVARIAN CARCINOMA

目的 :研究多个耐药基因P -糖蛋白 (P -gp)、谷胱甘肽S -转移酶 (GST -π)、DNA拓朴异构酶Ⅱ (Topo -Ⅱ )在卵巢癌组织中表达 ,探讨其在卵巢癌化学治疗耐药中的作用及与临床病理学特征间的关系。方法 :应用免疫组织化学技术 (SP法 )对 37例卵巢癌 ,10例卵巢良性肿瘤和 8例正常卵巢组织中P -gp、GST -π、Topo -Ⅱ表达状况进行测定。 结果 :P -gp、GST -π和Topo -Ⅱ在卵巢癌组织中阳性表达均高于良性肿瘤和正常组织对照组 ;GST -π、Topo -Ⅱ在低分化癌中阳性率明显高于中高分化癌 ,但与肿瘤组织类型无关。GST -π与临床分期有关。P -gp表达与卵巢癌组织类型、分化、分期均无关。 3者在卵巢癌组织中存在共同表达。结论 :卵巢癌存在原发性耐药并涉及多个耐药基因的共同表达。

Objective:To investigate the clinical significance of expression of P-glycoprotein (P-gp),glutathione-s-transferases(GST-π) and topoisomerase-Ⅱ(Topo-Ⅱ) in ovarian carcinoma tissues and evaluate their roles in chemoresistance of ovarian carcinoma.Methods:The expression of P-gp,GST-πand Topo-Ⅱin 37 cases of ovarian carcinoma,10 benign ovarian tumors and 7 normal controls were determined by using SP immunohitochemical technique,and the results were studied in the correlation with some clinical and pathological data.All the patients had not received chemothereapy before operations.Results:The positive expressions of P-gp,GST-πand Topo-Ⅱ in patients with ovarian carcinoma were all higher than these of the benign tumors and normal controls(P<0 05).A significant correlation was shown between GST-πand differentiated degree(P<0 005) and clinical stage(P<0 05).The expression level of Topo-Ⅱwas associated with differentiated degree (P<0 05).No significant difference with the expression of P-gp was found in relation to the histopathology,differentiated degree and clinical stage (P<0 05).Conclusion:Primary multidrug resistance really existing in ovarian carinoma Multiple gene co-expression is also involved in drugresistance in ovarian carcinoma.Combined determination of P-gp,GST-πand Topo-Ⅱmight be useful for predicting the chemosensitivities and chemoresponsiveness of ovarian carcinoma.